Search

Your search keyword '"Kusunoki, Y"' showing total 650 results
Start Over Author "Kusunoki, Y"
650 results on '"Kusunoki, Y"'

2. Long-term effects of gastrectomy in patients with spirometry-defined COPD and patients at risk of COPD: a case-control study

Author

Saito H, Nomura K, Abe S, Motegi T, Ishii T, Hattori K, Kusunoki Y, Gemma A, and Kida K

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Hitoshi Saito,1,2 Koichiro Nomura,1,2,† Shinji Abe,1,2 Takashi Motegi,2,3 Takeo Ishii,2,3 Kumiko Hattori,2,3 Yuji Kusunoki,2,3 Akihiko Gemma,2 Kozui Kida2,3 1Department of Respiratory Medicine, Tokyo Metropolitan Hiroo Hospital, 2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, 3Respiratory Care Clinic, Nippon Medical School †Koichiro Nomura passed away on July 30, 2014 Objective: Comorbidities are characteristic of COPD. However, little is known about the secondary manifestations of COPD in the gastrointestinal tract. Therefore, we aimed to explore the long-term effects of gastrectomy in patients with spirometry-defined COPD or those at risk of COPD.Participants: Subjects included 87 patients either with COPD or at risk of COPD (symptomatic) who underwent gastrectomy between December 2003 and October 2013 (group A), and 174 patients either with COPD or at risk of COPD, matched by age (±5 years), sex, and forced expiratory volume in 1 second (FEV1) as percentage of predicted (FEV1% predicted) (±5%) (group B).Methods: All patients underwent routine blood chemistry and pulmonary function tests, arterial blood gas analysis, 6-minute walk test (6MWT), high-resolution chest computed tomography scans, and nutritional assessments.Results: The mean duration postgastrectomy was 18.3±15.4 years. The mean FEV1 and FEV1% predicted were 2.07±0.76 L and 74.6±24.5%, respectively. Univariate analysis indicated that group A patients had significantly lower body mass index, fat-free mass index, and serum hemoglobin and albumin concentration (all P=0.00), and walked a significantly shorter distance in the 6MWT (P

Published
2015

3. Relationship between serum cardiac troponin T level and cardiopulmonary function in stable chronic obstructive pulmonary disease

Author

Hattori K, Ishii T, Motegi T, Kusunoki Y, Gemma A, and Kida K

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Kumiko Hattori, Takeo Ishii, Takashi Motegi, Yuji Kusunoki, Akihiko Gemma, Kozui Kida Department of Pulmonary Medicine and Oncology; Respiratory Care Clinic, Nippon Medical School, Tokyo, Japan Background: High-sensitivity cardiac troponin T (hs-cTnT) in serum is a useful marker of acute myocardial injury, yet information is limited in patients with chronic obstructive pulmonary disease. We aimed to explore the association between hs-cTnT levels and cardiac and pulmonary dysfunction in patients with stable chronic obstructive pulmonary disease and at-risk individuals. Methods: We examined community-dwelling adults with/without chronic obstructive pulmonary disease, with a life-long smoking history, current symptoms of dyspnea during exertion, prolonged coughing, and/or sputum. Serum hs-cTnT concentrations were measured, and subjects underwent pulmonary function tests, high-resolution computed tomography of the chest, an echocardiogram, and a 6-minute walking test. Results: Eighty-six stable patients were identified (mean age 65.5 years; predicted forced expiratory volume in 1 second [FEV1% predicted] 75.0%). Their overall mean hs-cTnT level was 0.008 ng/mL. Logarithmically transformed hs-cTnT levels significantly and positively correlated with age, smoking index, serum high-sensitivity C-reactive protein levels, right ventricle systolic pressure, low attenuation area percentage, and brain natriuretic peptide levels (range r=0.231–0.534, P=0.000 to P=0.042). Further, logarithmically transformed hs-cTnT values significantly and negatively correlated with forced vital capacity, FEV1% predicted, diffusion capacity, arterial oxygen tension, and 6-minute walking distance (range r= -0.482 to -0.377, P=0.000 to P=0.002). Multivariate analyses showed that hs-cTnT values varied independently according to the following three parameters: high-sensitivity C-reactive protein levels (B=0.157, ß=0.450, t=3.571, P=0.001), age (B=0.008, ß=0.352, t=2.789, P=0.009), and right ventricular systolic pressure (B=0.008, ß=0.280, t=2.202, P=0.035). Conclusion: Even in patients with stable chronic obstructive pulmonary disease, the serum troponin T concentration was controlled by at least three major factors, ie, systemic inflammation, advancing age, and right cardiac overload. Keywords: chronic obstructive pulmonary disease, troponin T, C-reactive protein, aging

Published
2015

4. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

Author

Konya H, Yano Y, Matsutani S, Tsunoda T, Ikawa T, Kusunoki Y, Matsuo T, Miuchi M, Katsuno T, Hamaguchi T, Miyagawa JI, and Namba M

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Hiroyuki Konya,1 Yuzo Yano,1 Satoshi Matsutani,1 Taku Tsunoda,2 Takashi Ikawa,2 Yoshiki Kusunoki,2 Toshihiro Matsuo,2 Masayuki Miuchi,2 Tomoyuki Katsuno,3 Tomoya Hamaguchi,4 Jun-ichiro Miyagawa,2 Mitsuyoshi Namba21Department of Internal Medicine, Ashiya Municipal Hospital, Ashiya, 2Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, 3Division of Innovative Diabetes Treatment, Hyogo College of Medicine, Nishinomiya, 4Division of Diabetes, Department of Internal Medicine, Itami City Hospital, Itami, Hyogo, JapanAbstract: Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 inhibitor, approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus (T2DM) in the USA on July 2009, and had been launched globally in over 86 countries by September 2013. In patients with T2DM, once-daily administration of saxagliptin before breakfast achieves sustained inhibition of plasma DPP-4 activity and reduction of postprandial hyperglycemia, including after dinner, associated with an increase in plasma glucagon-like peptide-1 levels. This paper reviews the safety and efficacy of saxagliptin in Japanese patients with T2DM. The clinical development study in Japan supported its usefulness for the disease. Saxagliptin 1, 2.5, and 5 mg led to significant improvements in glycated hemoglobin (HbA1c), and was generally well tolerated. Treatment with saxagliptin 5 mg induced a sustained reduction in HbA1c over 52 weeks. Long-term combination therapy with saxagliptin and other oral hypoglycemic agents also provided sustained glycemic control and was well tolerated for up to 52 weeks. Saxagliptin as add-on to sulfonylureas or glinides has a tendency to increase hypoglycemia, but not with other oral antidiabetic agents, such as α-glucosidase inhibitors, metformin, or thiazolidinediones. The results of clinical trials have confirmed the long-term efficacy and safety of saxagliptin monotherapy as well as its use as add-on combination therapy, and support its usefulness as a therapeutic agent for T2DM. Saxagliptin has less concern for hypoglycemia and weight gain, which often becomes problematic in routine care of T2DM. Meta-analysis of clinical trials in the USA showed no evidence of increased risk of cardiovascular events associated with saxagliptin, suggesting the superior of saxagliptin in terms of safety. Recently, investigators in the SAVOR-TIMI (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction) 53 study suggested that DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, although the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. Saxagliptin is applicable for various pathological conditions, and is considered to be clinically significant as a new therapeutic option for Japanese patients with T2DM.Keywords: dipeptidyl peptidase-4, incretin hormones, saxagliptin, type 2 diabetes mellitus, Japan, efficacy, safety, patient acceptability

Published
2014

5. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations

Author

Motegi T, Jones RC, Ishii T, Hattori K, Kusunoki Y, Furutate R, Yamada K, Gemma A, and Kida K

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Takashi Motegi,1,2 Rupert C Jones,3 Takeo Ishii,1,2 Kumiko Hattori,1,2 Yuji Kusunoki,1,2 Ryuko Furutate,2 Kouich Yamada,1,2 Akihiko Gemma,1 Kozui Kida1,2 1Divisions of Pulmonary Medicine, Infectious Disease, and Oncology, Department of Internal Medicine, 2Respiratory Care Clinic, Nippon Medical School, Tokyo, Japan; 3Respiratory Research Unit, Peninsula Medical School, Plymouth, UK Background: Prediction of future exacerbations of chronic obstructive pulmonary disease (COPD) is a major concern for long-term management of this disease. Aim: To determine which of three multidimensional assessment systems (the body mass index, obstruction, dyspnea, and exercise capacity [BODE] index; dyspnea, obstruction, smoking, exacerbations [DOSE] index; or age, dyspnea, obstruction [ADO] index) is superior for predicting exacerbations. Methods: This was a 2-year prospective cohort study of COPD patients. Pulmonary function tests, the 6-minute walk distance (6MWD), Modified Medical Respiratory Council (MMRC) dyspnea scores, chest computed-tomography measurements, and body composition were analyzed, and predictions of exacerbation by the three assessment systems were compared. Results: Among 183 patients who completed the study, the mean annual exacerbation rate was 0.57 events per patient year, which correlated significantly with lower predicted forced expiratory volume in 1 second (FEV1) (P < 0.001), lower transfer coefficient of the lung for carbon monoxide (%DLco/VA) (P = 0.021), lesser 6MWD (P = 0.016), higher MMRC dyspnea score (P = 0.001), higher DOSE index (P < 0.001), higher BODE index (P = 0.001), higher ADO index (P = 0.001), and greater extent of emphysema (P = 0.002). For prediction of exacerbation, the areas under the curves were larger for the DOSE index than for the BODE and ADO indices (P < 0.001). Adjusted multiple logistic regression identified the DOSE index as a significant predictor of risk of COPD exacerbation. Conclusion: In this study, the DOSE index was a better predictor of exacerbations of COPD when compared with the BODE and ADO indices. Keywords: frequency of exacerbation, multidimensional assessment systems, DOSE index, BODE index

Published
2013

13. The advanced lung cancer inflammation index predicts outcomes in patients with Crohn’s disease after surgical resection

Author

Kusunoki, K., primary, Toiyama, Y., additional, Okugawa, Y., additional, Yamamoto, A., additional, Omura, Y., additional, Kusunoki, Y., additional, Yin, C., additional, Kondo, S., additional, Okita, Y., additional, Ohi, M., additional, Sasaki, H., additional, Bando, T., additional, Uchino, M., additional, Ikeuchi, H., additional, and Kusunoki, M., additional

Published
2020
Full Text
View/download PDF

19. TRANSCUTANEOUS NEEDLE BIOPSY OF THE LUNG

Author

Komiya, T., Kusunoki, Y., Kobayashi, M., Hirashima, T., Yana, T., Masuda, N., Matsui, K., Takada, M., Nakagawa, K., Kotake, Y., Yasumitsu, T., Kikui, M., and Kawase, I.

Published
1997

22. The advanced lung cancer inflammation index predicts outcomes in patients with Crohn's disease after surgical resection.

Author

Kusunoki, K., Toiyama, Y., Okugawa, Y., Yamamoto, A., Omura, Y., Kusunoki, Y., Yin, C., Kondo, S., Okita, Y., Ohi, M., Sasaki, H., Bando, T., Uchino, M., Ikeuchi, H., and Kusunoki, M.

Subjects
CROHN'S disease, PNEUMONIA, LUNG cancer, SURGICAL excision, PROGNOSIS, LOBECTOMY (Lung surgery)
Abstract

Aim: Precise biomarkers for predicting prognosis could help to identify high‐risk Crohn's disease (CD) patients to facilitate better follow‐up during the postoperative course. In this study, the primary aim is the identification of the most reliable nutrition marker that predicts surgical relapse in CD patients. Method: We first evaluated the predictive value of various nutrition markers for postoperative surgical relapse in CD patients and identified the advanced lung cancer inflammation index (ALI) as a promising biomarker. Then, we assessed the clinical significance of preoperative ALI in CD patients using two cohorts. Results: Preoperative ALI showed the highest correlation with reoperation rate compared with other nutritional parameters in CD patients receiving surgical resection (sensitivity 53%, specificity 86%, area under the curve 0.71). Lower levels of preoperative ALI were significantly correlated with the presence of perianal disease. A lower level of preoperative ALI was an independent prognostic factor for reoperation rate after an intestinal resection (hazard ratio 3.37, 95% CI 1.38–10.12, P = 0.006), and the prognostic impact of preoperative ALI was successfully validated in an independent cohort using the same cut‐off value. Conclusion: Preoperative ALI might be useful for postoperative management of CD patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. THU0388 Menatetrenone (Vitamin K2) Partially Restores the Suppression of Bone Formation by Glucocorticoid Therapy in Patients with Systemic Autoimmune Diseases

Author

Shikano, K., primary, Kaneko, K., additional, Muraoka, S., additional, Kaburaki, M., additional, Kitahara, K., additional, Tanaka, N., additional, Yamamoto, T., additional, Kusunoki, Y., additional, Takagi, K., additional, Hasunuma, T., additional, Endo, H., additional, and Kawai, S., additional

Published
2013
Full Text
View/download PDF

41. AKI - experimental models

Author

Lai, C.-F., primary, Lin, S.-L., additional, Chiang, W.-C., additional, Chen, Y.-M., additional, Kuo, M.-L., additional, Tsai, T.-J., additional, Hwang, H. S., additional, Choi, Y. A., additional, Park, K. C., additional, Yang, K. J., additional, Choi, H. S., additional, Kim, S. H., additional, Lee, S. J., additional, Chang, Y. K., additional, Kim, S. Y., additional, Yang, C. W., additional, Xiujuan, Z., additional, Yoshimura, R., additional, Matsuyama, M., additional, Chargui, J., additional, Touraine, J.-L., additional, Yoshimura, N., additional, Zulkarnaev, A. B., additional, Vasilenko, I. A., additional, Artemov, D. V., additional, Vatazin, A. V., additional, Park, S. K., additional, Kang, K. P., additional, Lee, S., additional, Kim, W., additional, Schneider, R., additional, Betz, B., additional, Moller-Ehrlich, K., additional, Wanner, C., additional, Sauvant, C., additional, Park, C. W., additional, Sohotnik, R., additional, Nativ, O., additional, Abbasi, A., additional, Awad, H., additional, Frajewicki, V., additional, Armaly, Z., additional, Heyman, S. N., additional, Abassi, Z., additional, Chen, P. Y., additional, Chen, B. L., additional, Yang, C. C., additional, Chiang, C. K., additional, Liu, S. H., additional, Abozahra, A. E., additional, Abd-Elkhabir, A. A., additional, Shokeir, A., additional, Hussein, A., additional, Awadalla, A., additional, Barakat, N., additional, Abdelaziz, A., additional, Yamaguchi, J., additional, Tanaka, T., additional, Eto, N., additional, Nangaku, M., additional, Quiros, Y., additional, Lopez-Hernandez, F. J., additional, Perez de Obanos, M. P., additional, Ruiz, J., additional, Lopez-Novoa, J. M., additional, Shin, H.-S., additional, Kim, M.-J., additional, Choi, Y.-J., additional, Ryu, E.-S., additional, Choi, H.-S., additional, Kang, D.-H., additional, Jankauskas, S. S., additional, Pevzner, I. B., additional, Zorova, L. D., additional, Babenko, V. A., additional, Morosanova, M. A., additional, Plotnikov, E. Y., additional, Zorov, D. B., additional, Huang, C.-Y., additional, Huang, T.-M., additional, Wu, V.-C., additional, Young, G.-H., additional, Chupyrkina, A. A., additional, Zorov, S. D., additional, Grande, J. P., additional, Hartono, S. P., additional, Knudsen, B. E., additional, Mederle, K., additional, Castrop, H., additional, Hocherl, K., additional, Iwakura, T., additional, Fujikura, T., additional, Ohashi, N., additional, Yasuda, H., additional, Fujigaki, Y., additional, Matsui, I., additional, Hamano, T., additional, Inoue, K., additional, Obi, Y., additional, Nakano, C., additional, Kusunoki, Y., additional, Tsubakihara, Y., additional, Rakugi, H., additional, Isaka, Y., additional, Shimomura, A., additional, Wallentin Guron, C., additional, Nguy, L., additional, Lundgren, J., additional, Grimberg, E., additional, Kashioulis, P., additional, Guron, G., additional, DiBona, G. F., additional, Nedergaard Mikkelsen, M., additional, Marcussen, N., additional, Saeed, A., additional, Edvardsson, K., additional, Lindberg, K., additional, Larsson, T., additional, Ito, K., additional, Nakashima, H., additional, Watanabe, M., additional, Abe, Y., additional, Ogahara, S., additional, Saito, T., additional, Albertoni, G., additional, Borges, F., additional, Schor, N., additional, Beresneva, O. N., additional, Parastayeva, M. M., additional, Kucher, A. G., additional, Ivanova, G. T., additional, Shved, N., additional, Rybakova, M. G., additional, Kayukov, I. G., additional, Smirnov, A. V., additional, Chen, J.-F., additional, Ni, H.-F., additional, Pan, M.-M., additional, Liu, H., additional, Xu, M., additional, Zhang, M.-H., additional, Liu, B.-C., additional, Kim, Y., additional, Choi, B. S., additional, Kim, Y. S., additional, Han, J. S., additional, Reis, L. A., additional, Christo, J. S., additional, Simoes, M. d. J., additional, Mulay, S. R., additional, Santhosh Kumar, V. R., additional, Kulkarni, O. P., additional, Darisipudi, M., additional, Lech, M., additional, Anders, H.-J., additional, Silachev, D. N., additional, Sola, A., additional, Jung, M., additional, Ventayol, M., additional, Mastora, C., additional, Buenestado, S., additional, Hotter, G., additional, Rong, S., additional, Shushakova, N., additional, Wensvoort, G., additional, Haller, H., additional, Gueler, F., additional, Morais, C., additional, Vesey, D. A., additional, Johnson, D. W., additional, Gobe, G. C., additional, Godo, M., additional, Kaucsar, T., additional, Revesz, C., additional, Hamar, P., additional, Cheng, Q., additional, Wen, J., additional, Ma, Q., additional, Zhao, J., additional, Castellano, G., additional, Stasi, A., additional, Di Palma, A. M., additional, Gigante, M., additional, Netti, G. S., additional, Curci, C., additional, Intini, A., additional, Divella, C., additional, Prattichizzo, C., additional, Fiaccadori, E., additional, Pertosa, G., additional, Grandaliano, G., additional, Gesualdo, L., additional, Wei, Q. W., additional, Jing, Q. Q., additional, Ying, N. J., additional, Dong, Q. Z., additional, Yong, G., additional, Pulkova, N. V., additional, Sukhikh, G. T., additional, Kim, S., additional, Lee, J., additional, Nam, N. J., additional, Na, K. Y., additional, Ma, S. K., additional, Joo, S. Y., additional, Kim, C. S., additional, Choi, J. S., additional, Bae, E. H., additional, Kim, S. W., additional, Cernaro, V., additional, Medici, M. A., additional, Donato, V., additional, Trimboli, D., additional, Lorenzano, G., additional, Santoro, D., additional, Montalto, G., additional, Buemi, M., additional, Longo, V., additional, Segreto, H. R. C., additional, Almeida, W., additional, Ramos, M. F., additional, Gomes, L., additional, Razvickas, C., additional, Gutberlet, M., additional, Meier, M., additional, Mengel, M., additional, Wacker, D., additional, Hueper, K., additional, Uzum, A., additional, Ersoy, R., additional, Cakalagaoglu, F., additional, Karaman, M., additional, Kolatan, E., additional, Sahin, O., additional, Yilmaz, O., additional, Cirit, M., additional, Inal, S., additional, Koc, E., additional, Okyay, G. U., additional, Pasaoglu, O., additional, Gonul, I., additional, Oyar, E., additional, Pasaoglu, H., additional, Guz, G., additional, Sabbatini, M., additional, Rossano, R., additional, Andreucci, M., additional, Pisani, A., additional, Riccio, E., additional, Choi, D. E., additional, Jeong, J. Y., additional, Kim, S. S., additional, Na, K.-R., additional, Lee, K. W., additional, Shin, Y. T., additional, Silva, A. F., additional, Teixeira, V. C., additional, Meszaros, K., additional, Koleganova-Gut, N., additional, Schaefer, F., additional, Ritz, E., additional, Walacides, D., additional, Ruskamp, N., additional, Schiffer, M., additional, Marom, O., additional, Haick, H., additional, Nakhoul, F., additional, Lv, L.-L., additional, Tang, R.-N., additional, Zhang, J.-D., additional, Ma, K.-L., additional, Chen, P.-S., additional, Ko, W.-J., additional, Misiara, G. P., additional, Coimbra, T. M., additional, Silva, G. E. B., additional, Costa, R. S., additional, Francescato, H. D. C., additional, Neto, M. M., additional, Dantas, M., additional, Olauson, H., additional, Amin, R., additional, Ponnusamy, A., additional, Goetz, R., additional, Mohammadi, M., additional, Canfield, A., additional, Kublickiene, K., additional, Rodriguez, J., additional, Reyes, E. P., additional, Cortes, P. P., additional, Fernandez, R., additional, Yoon, H. E., additional, Koh, E. S., additional, Chung, S., additional, Shin, S. J., additional, Pazzano, D., additional, Lupica, R., additional, Torre, F., additional, Costantino, G., additional, Prieto, M., additional, Gonzalez-Buitrago, J. M., additional, Lopez-Hernandez, F., additional, Morales, A. I., additional, Vicente-Vicente, L., additional, Ferreira, L., additional, Simoes, M. J., additional, Passos, C. d., additional, Schor, N. S., additional, Shimizu, M. H. M., additional, Canale, D., additional, de Braganca, A. C., additional, Andrade, L., additional, Luchi, W. M., additional, Seguro, A. C., additional, Goncalves, J., additional, Volpini, R. A., additional, Garrido, P., additional, Fernandes, J., additional, Ribeiro, S., additional, Vala, H., additional, Parada, B., additional, Alves, R., additional, Belo, L., additional, Costa, E., additional, Santos-Silva, A., additional, and Reis, F., additional

Published
2013
Full Text
View/download PDF

43. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT

Author

Yoshihara, S, primary, Maruya, E, additional, Taniguchi, K, additional, Kaida, K, additional, Kato, R, additional, Inoue, T, additional, Fujioka, T, additional, Tamaki, H, additional, Ikegame, K, additional, Okada, M, additional, Soma, T, additional, Hayashi, K, additional, Fujii, N, additional, Onuma, T, additional, Kusunoki, Y, additional, Saji, H, additional, and Ogawa, H, additional

Published
2011
Full Text
View/download PDF

47. Pleiotropic Effects of Mitiglinide in Type 2 Diabetes Mellitus

Author

Konya, H, primary, Miuchi, M, additional, Konishi, K, additional, Nagai, E, additional, Ueyama, T, additional, Kusunoki, Y, additional, Kimura, Y, additional, Nakamura, Y, additional, Ishikawa, T, additional, Inokuchi, C, additional, Katsuno, T, additional, Hamaguchi, T, additional, Miyagawa, J, additional, and Namba, M, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results